The Manufacturers Life Insurance Company Buys 399 Shares of RxSight, Inc. (NASDAQ:RXST)

The Manufacturers Life Insurance Company increased its position in RxSight, Inc. (NASDAQ:RXST) by 1.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,911 shares of the company’s stock after acquiring an additional 399 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.05% of RxSight worth $1,034,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank raised its holdings in RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after buying an additional 207 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of RxSight by 0.7% in the third quarter. Principal Financial Group Inc. now owns 36,046 shares of the company’s stock worth $1,782,000 after acquiring an additional 240 shares during the period. Crossmark Global Holdings Inc. raised its holdings in shares of RxSight by 3.2% during the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after purchasing an additional 242 shares during the last quarter. RiverPark Advisors LLC lifted its position in RxSight by 9.6% during the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after purchasing an additional 297 shares during the period. Finally, CWM LLC boosted its position in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after purchasing an additional 371 shares during the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,225,096.82. The trade was a 6.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jesse Anderson Corley bought 11,111 shares of RxSight stock in a transaction that occurred on Tuesday, November 12th. The shares were acquired at an average cost of $45.37 per share, with a total value of $504,106.07. Following the acquisition, the director now owns 468,571 shares of the company’s stock, valued at $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 65,807 shares of company stock worth $3,202,275 over the last 90 days. 9.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wells Fargo & Company reiterated an “equal weight” rating and set a $42.00 target price (down previously from $56.00) on shares of RxSight in a research report on Wednesday. Jefferies Financial Group began coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of RxSight in a research note on Friday, September 13th. Finally, UBS Group started coverage on RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $62.13.

RxSight Price Performance

Shares of RXST stock opened at $35.89 on Friday. The stock’s 50-day moving average is $47.21 and its 200 day moving average is $51.02. The company has a market cap of $1.45 billion, a P/E ratio of -43.24 and a beta of 1.11. RxSight, Inc. has a 1-year low of $34.92 and a 1-year high of $66.54.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.